Palantir will soon help the FDA evaluate drugs, including COVID-19 treatments

Palantir will soon help the FDA evaluate drugs, including COVID-19 treatments

Although it isn’t clear if the Biden administration will continue to expand federal work with Palantir, the process of distributing vaccines provides another logistical opportunity for the controversial company. Tracking which individuals have received both doses of a vaccine is work that sounds very much in Palantir’s wheelhouse.

Emergency approval of coronavirus vaccines is not guaranteed, FDA commissioner says

Emergency approval of coronavirus vaccines is not guaranteed, FDA commissioner says

Career scientists at the FDA are reviewing raw data from the Pfizer and Moderna trials for the first time, investigating any adverse events or side effects that transpired over the course of the trials, different levels of effectiveness among populations and age groups, and whether individuals who were already infected by the coronavirus might have had any unexpected reactions to the vaccine doses.

Hahn said they will also be looking for evidence that the vaccines lead to increased respiratory infections – a concern with vaccines produced for other coronaviruses, such as SARS and MERS – and whether the use of a relatively new method of vaccine development, known as messenger RNA technology, poses any significant risks.